‘Navigating the Biopharma Services Lanscape: Current Trends and Future Perspectives’ at BIO-Europe - interesting discussions regarding price vs value in service providers. Speed, flexibility, dependability and quality are key considerations when delivering novel molecules to the clinic, not just cost, and a track record of delivering success commands a premium Sygnature Discovery #BioEurope
Kerry Waters BSc. MBA’s Post
More Relevant Posts
-
🤝Do you want to experience the Power of Ecosystems ? 🤝 In a fast-evolving world, innovation thrives when it’s collaborative. That’s why ecosystems like Living Tomorrow are so crucial. They bring together forward-thinking companies, research institutions, and individuals to co-create solutions for a sustainable future. The Living Tomorrow Innovation Campus is the unique cross-pollination of a physical location, an impressive ecosystem and a strong vision on innovation. At Multipharma, we’re proud to have participated in today’s Future Forward event, embracing the collaborative spirit to drive innovation and achieve our mission. This ecosystem allows us to tackle challenges together and create impactful solutions that benefit both our industry and society. Because moving forward is the only way to continue to improve access to the best pharmaceutical care for all. #Innovation #Sustainability #Multipharma #LivingTomorrow #Pharmacistsprovidecare Joachim De Vos Yin Oei Frank Belien Jurgen De Jaeger Peter De Greef Delphine Hajaji Stephane Bouillon
To view or add a comment, sign in
-
In early to mid-stage biotech, you’re often juggling multiple responsibilities -- managing clinical trials can be just one of many responsibilities. In this video clip from our event earlier this summer, Divya Chadha Manek OBE discusses the challenges that come with wearing many hats. It helps emphasize why it’s essential to have the right partners and support in place to ensure trial success. Missed the event? Watch the full on-demand videos to explore strategies for managing clinical trials more effectively and discover how Yourway can help simplify the process. https://lnkd.in/gTTm6ZrY #Biotech #ClinicalTrials #PharmaLogistics #DublinDepot #DrugDiscovery #Partner
To view or add a comment, sign in
-
Thrilled to be participating in today’s #BioEquity Europe discussion: “Dealmakers Showcase: How to Grab the Attention of Pharma BD&L Execs.” Join me and the other panelists at 2pm as we delve into what biotechs must do to rise above the noise to secure partnerships that drive innovation and growth with big pharma. I look forward to connecting with fellow leaders and innovators who are shaping the future of healthcare. #BioEquity #JNJInnovation
To view or add a comment, sign in
-
🌟 𝐇𝐮𝐠𝐞 𝐭𝐡𝐚𝐧𝐤𝐬 𝐭𝐨 𝐨𝐮𝐫 𝐟𝐚𝐧𝐭𝐚𝐬𝐭𝐢𝐜 𝐩𝐚𝐧𝐞𝐥𝐢𝐬𝐭𝐬 𝐟𝐨𝐫 𝐬𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 𝐫𝐨𝐥𝐞 𝐨𝐟 𝐂𝐌𝐂 𝐢𝐧 𝐭𝐡𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐫𝐨𝐚𝐝𝐦𝐚𝐩! 🌟 Their insights made it clear that CMC decisions can significantly impact asset valuation and out-licensing potential. A standout moment? 🚨 Corinne Venot’s eye-opening statistic: 𝐨𝐯𝐞𝐫 𝟓𝟎% 𝐨𝐟 𝐝𝐮𝐞 𝐝𝐢𝐥𝐢𝐠𝐞𝐧𝐜𝐞𝐬 𝐟𝐚𝐢𝐥, 𝐨𝐫 𝐚𝐬𝐬𝐞𝐭𝐬 𝐚𝐫𝐞 𝐝𝐞𝐯𝐚𝐥𝐮𝐞𝐝, 𝐝𝐮𝐞 𝐭𝐨 𝐂𝐌𝐂 𝐢𝐬𝐬𝐮𝐞𝐬 in her Pharma licensing experience. And Johannes Roebers shared a compelling case about a topical product that reached Phase III, only to fail because formulation and delivery systems were overlooked early on—an end to what could’ve been a great biotech story. 💡 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐨𝐫 𝐁𝐢𝐨𝐭𝐞𝐜𝐡𝐬: 1.𝗜𝗻𝘃𝗲𝘀𝘁 𝗶𝗻 𝗖𝗠𝗖! Biotechs often underestimate CMC strategy and execution budgets. 2. 𝗗𝗲𝘀𝗶𝗴𝗻 𝘁𝗵𝗲 𝗖𝗠𝗖 𝗿𝗼𝗮𝗱𝗺𝗮𝗽 𝗲𝗮𝗿𝗹𝘆 to ensure your tox material matches the future GMP process/platform/CDMO. 3. 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗲 𝗘𝘅𝗽𝗲𝗿𝘁𝘀 with deep experience in the field to avoid later pitfalls, in both Drug Substance and Formulation/Drug Product aspects. 4. 𝗨𝘀𝗲 𝗣𝗿𝗼𝘃𝗲𝗻 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀/𝗖𝗗𝗠𝗢𝘀. Stick to innovating the asset/not the process—ensure future CMC transferability to a commercial Pharma/CDMO site. 5. 𝗧𝗵𝗶𝗻𝗸 𝗕𝗲𝘆𝗼𝗻𝗱 𝗣𝗵𝗮𝘀𝗲 𝗜! Plan for scalability, transferability, and early de-risking of commercial COGS with market access in mind. Our discussion highlighted that 𝗖𝗠𝗖 𝗰𝗮𝗻 𝗲𝗶𝘁𝗵𝗲𝗿 𝗼𝗽𝗲𝗻 𝗱𝗼𝗼𝗿𝘀 𝗳𝗼𝗿 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗼𝗿 𝗰𝗿𝗲𝗮𝘁𝗲 𝗿𝗼𝗮𝗱𝗯𝗹𝗼𝗰𝗸𝘀 at the out-licensing stage. And while CMC might be seen as a “boring topic” by investors (thanks Matthieu Coutet for the candid statement!), it’s under more scrutiny than ever. 🚀 𝗠𝗲𝘀𝘀𝗮𝗴𝗲 𝘁𝗼 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵𝘀: 𝗺𝗮𝗸𝗲 𝗖𝗠𝗖 𝗮 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝘆—𝘁𝗵𝗶𝘀 𝗲𝗮𝗿𝗹𝘆 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝘄𝗶𝗹𝗹 𝘀𝗲𝘁 𝘆𝗼𝘂 𝘂𝗽 𝗳𝗼𝗿 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝘀𝘂𝗰𝗰𝗲𝘀𝘀! #BioEurope #ProductDevelopment #CMC #AssetValuation #BioPharma #ProductLifeGroup #Sofinnova #Beigene # AGCBiologics #NioSync
🌟 Another great panel addressing CMC development from investor, Biotech and CDMO perspectives 🌟 We were honored to host this conversation at EBD Group Bio-Europe Fall, on the topic of CMC development – an aspect that is often time overlooked but plays a crucial role in biotech asset valuation . A big thank you to our esteemed panelists: Johannes Roebers, PhD (ProductLife Group), Matthieu Coutet (Sofinnova Partners), Christoph Winterhalter (AGC Biologics), Corinne VENOT (BeiGene), Neil McLoughlin (NíoSync Limited) and our moderator Christelle Dagoneau (ProductLife Group) for their valuable contributions and insights on this topic. 🔗 Want to learn yourself from the experts? Access the full recording here: https://lnkd.in/eCTg7tRS Make the most out of your day 3 of Bio-Europe! Stop by Booth 45 to meet with: Geary H., Fernando Mayoral Alonso, Christelle Dagoneau, Johannes Roebers, PhD and Maria Cristina Cadena Laso and discuss how we can support your Product Development needs. #PLGEvent #Biotech #pharma #innovation #healthcare #productdevelopment #lifescience #CMC #Biopharma #BioEurope
To view or add a comment, sign in
-
It’s now just 1 Month until Stuart Hunter, Business Development Lead, will be in #TheBigApple attending the BIO CEO & Investor Conference 2025, with partnering still open! The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded, late-stage private biotech companies. The conference provides a yearly forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotech industry. This years event, hosted in New York City, will feature a number of issue-oriented plenary sessions and fireside chats on hot-topics such as obesity medications, the use of AI in drug development, and how to successfully navigate the challenges when commercialising a product. In addition, there will be company presentations focussing on the latest innovations in biotech, and plenty of networking opportunities including those important partnering meetings! If you will also be attending, don’t miss the chance to meet with Stuart to discuss how our experts at DLRC can support your biotech company and products to navigate a variety of challenges during development, through to product commercialisation and beyond. Request a meeting by searching for DLRC in the BIO Partnering™ system, or email us at hello@dlrcgroup.com #BIOCEO25 #InnovationInBiotech #PharmaEvents #RegulatoryAffairs #NYC
To view or add a comment, sign in
-
Should biotech companies consider pricing implications for Early Access Programs? In this snippet from our recent webinar with Fierce Biotech, Andrew Cummins (VP of Business Development) gives his expert thoughts and advice. Download valuable insights from our latest webinar! Visit: https://lnkd.in/eP4C3bFU #ExpandedAccessPrograms #RareDiseases #OrphanDrugs #RealWorldEvidence #MarketAccess #biotechs Mathieu Loiseau Sara Radenovic
To view or add a comment, sign in
-
Overcoming Obstacles and Seizing Opportunities in Early Phase Biotech Research. Access your free roundtable report now: https://ow.ly/tPtS50SBoOo. In this report in partnership with ICON plc, discover insights from leading biotechs on: • Different challenges of each development stage • CRO selection criteria and scoring tools • Additional CRO value vs. traditional value proposition #BiotechResearch #EarlyPhaseBiotech #RoundtableReport #BiotechInsights #ClinicalResearch #PharmaDevelopment
To view or add a comment, sign in
-
At #ASH24, our CEO John V. Oyler connected with Brad Loncar of BiotechTV to discuss the exciting progress in our pipeline and how BeiGene's investments in global scale are bearing fruition. Watch the full discussion here: https://ow.ly/ulCI50UnT7Z
To view or add a comment, sign in
-
Novo Holdings has deployed USD $11.1 billion into life science companies over the past 5 years. We are currently the partner to 180 companies across life science subsectors – from #biotech and biopharma, to #medtech, healthcare IT, tools #diagnostics and pharma services. We aspire to be a catalyst for change by investing in companies that share in our mission to improve human and planetary health. #JPM2025
To view or add a comment, sign in
-
Join us for at our joint Breakfast Seminar with World Courier "From Molecule to Market: Navigating the Complexities of Drug Development”. 📅 April 25, 2024 | 8:30am CET 📍 BioM Biotech Cluster Development GmbH, Martinsried In this informative morning discussion as we delve into the journey from scientific breakthroughs to market success. Our expert speakers will explore the complex process of transforming groundbreaking molecules into marketable products, offering valuable insights and strategies for success. Learn more and register here: 🔗 https://lnkd.in/djr56EGe Key Takeaways: ✅ Understand global regulatory landscapes in Europe and the US ✅ Learn successful market access strategies, focusing on the German and European markets ✅ Explore logistics management from early development to commercialization ✅ Engage in an interactive Q&A session with industry experts Can't join in person? Register for online attendance to access valuable insights from anywhere: 🔗 https://shorturl.at/bv036 Don't miss out on this opportunity to enhance your drug development strategies. #CencoraPharmalex #DrugDevelopment #RegulatoryAffairs
To view or add a comment, sign in